{"DataElement":{"publicId":"2685168","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis Disease or Disorder Classification Type","preferredDefinition":"A description of the congenital metabolic or osteopetrosis disorder classification.","longName":"MTBLC_DS_CLS_TP","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2685166","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis Disease or Disorder Classification","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero._Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY)._Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. Sometimes the term is used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function._A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","longName":"MTBLC_DS_CLS","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2685164","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis Diseases and Disorders","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.:Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).:A definite pathologic process with a characteristic set of signs and symptoms. It may affect the whole body or any of its parts, and its etiology, pathology, and prognosis may be known or unknown.","longName":"C34816:C26840:C2991","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Disease or Disorder","conceptCode":"C2991","definition":"Any abnormal condition of the body or mind that causes discomfort, dysfunction, or distress to the person affected or those in contact with the person. The term is often used broadly to include injuries, disabilities, syndromes, symptoms, deviant behaviors, and atypical variations of structure and function.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B96C0A4-24E0-191A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2321361","version":"1","preferredName":"Classification","preferredDefinition":"Classification; the grouping of things into classes or categories.","longName":"C25161","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Classification","conceptCode":"C25161","definition":"A method of generalization, the systematic arrangement of entities into classes or groups based on mutual similarity and certain differing characteristics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"FCF89106-20AF-2D93-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-29","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-29","modifiedBy":"ONEDATA","dateModified":"2005-07-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B96C0A4-24EE-191A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2685147","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis Type","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero._Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY)._Something distinguishable as an identifiable class based on common qualities.","longName":"MTBLC_DSRDR_TP","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"61","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Inherited Disorders or Metabolism, NOS","valueDescription":"Not Otherwise Specified Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2685148","version":"1","preferredName":"Not Otherwise Specified Congenital Metabolic Disorder","longName":"2685148","preferredDefinition":"Not characterized in any other way.: Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-73A4-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-73BD-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Other inherited disorder of metabolism","valueDescription":"Other Congenital Metabolic Disorder","ValueMeaning":{"publicId":"2685149","version":"1","preferredName":"Other Congenital Metabolic Disorder","longName":"2685149","preferredDefinition":"Not otherwise specified.: Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-73CC-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-73E5-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Wolman disease","valueDescription":"Wolman disease","ValueMeaning":{"publicId":"2579871","version":"1","preferredName":"Wolman disease","longName":"2579871v1.00","preferredDefinition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Wolman Disease","conceptCode":"C61271","definition":"A very rare, autosomal recessive inherited lysosomal storage disease caused by mutations in the LIPA gene. Signs and symptoms appear in infancy and include developmental delay, vomiting, abdominal distention, hepatosplenomegaly, jaundice, anemia, steatorrhea, and calcification of the adrenal glands.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-050C-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-73F1-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Scheie syndrome (IS)","valueDescription":"Scheie Syndrome","ValueMeaning":{"publicId":"2582069","version":"1","preferredName":"Scheie Syndrome","longName":"2582069","preferredDefinition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.\r\n","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Scheie Syndrome","conceptCode":"C61265","definition":"An autosomal recessive disorder representing the milder form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase. Signs and symptoms include broad mouth with full lips, cloudy cornea which may lead to blindness, stiff joints, and hirsutism.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DA2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7406-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Sanfilippo (III)","valueDescription":"Sanfilippo Syndrome","ValueMeaning":{"publicId":"2593469","version":"1","preferredName":"Sanfilippo Syndrome","longName":"2593469v1.00","preferredDefinition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides. Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Sanfilippo Syndrome","conceptCode":"C61262","definition":"A rare autosomal recessive lysosomal storage disease affecting the metabolism of mucopolysaccharides. Signs and symptoms include behavioral changes, sleep disorders, mental developmental delays, and seizures.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBEDF7-5116-56DB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7412-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Polysaccharide hydrolase abnormalities, NOS","valueDescription":"Polysaccharide hydrolase abnormalities, NOS","ValueMeaning":{"publicId":"2685150","version":"1","preferredName":"Polysaccharide hydrolase abnormalities, NOS","longName":"2685150v1.00","preferredDefinition":"Not characterized in any other way._An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars._A condition that differs from the usual physical or mental state.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Polysaccharide Hydrolase","conceptCode":"C99387","definition":"An enzyme that hydrolyzes the breakdown of a polysaccharide to simple sugars.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Abnormality","conceptCode":"C9440","definition":"A condition that differs from the usual physical or mental state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-741E-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"KUMMEROA","dateModified":"2024-01-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7437-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Osteopetrosis (malignant infantile osteopetrosis)","valueDescription":"Osteopetrosis","ValueMeaning":{"publicId":"2593448","version":"1","preferredName":"Osteopetrosis","longName":"2593448","preferredDefinition":"Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAB4E-68BC-4B19-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-744C-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Neuronalceroid lipofuscinosis (Batten disease)","valueDescription":"Batten Disease","ValueMeaning":{"publicId":"2593458","version":"1","preferredName":"Batten Disease","longName":"2593458v1.00","preferredDefinition":"A condition associated with mutation(s) in the CLN3 gene, encoding battenin. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Neuronal Ceroid Lipofuscinosis Type 3","conceptCode":"C61258","definition":"A condition associated with mutation(s) in the CLN3 gene, encoding battenin. The condition is one of a group of genetically heterogeneous neurodegenerative disorders, characterized by accumulation of intracellular lipopigments.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAD41-DCA2-4B7F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7461-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Niemann-Pick disease","valueDescription":"Niemann-Pick disease","ValueMeaning":{"publicId":"2579869","version":"1","preferredName":"Niemann-Pick disease","longName":"2579869v1.00","preferredDefinition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Niemann-Pick Disease","conceptCode":"C61269","definition":"An autosomal recessive inherited lysosomal storage disease characterized by deficiency of sphingomyelinase. It results in the accumulation of sphingomyelin in the liver, spleen, brain, lungs, and bone marrow. Signs and symptoms include hepatosplenomegaly, pancytopenia, ataxia, dystonia, and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-050A-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-746D-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis, not otherwise specified","valueDescription":"Not Otherwise Specified Mucopolysaccharidosis","ValueMeaning":{"publicId":"2685151","version":"1","preferredName":"Not Otherwise Specified Mucopolysaccharidosis","longName":"2685151v1.00","preferredDefinition":"Not characterized in any other way._A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-747C-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7495-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Mucopolysaccharidosis (V)","valueDescription":"Mucopolysaccharidosis","ValueMeaning":{"publicId":"2593463","version":"1","preferredName":"Mucopolysaccharidosis","longName":"2593463v1.00","preferredDefinition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mucopolysaccharidosis","conceptCode":"C61259","definition":"A group of autosomal recessive or X-linked inherited lysosomal storage disorders affecting the metabolism of mucopolysaccharides, resulting in the accumulation of mucopolysaccharides in the body. Signs and symptoms include organomegaly, intellectual disabilities, abnormal skeletal development, heart disorders, hearing loss, and central nervous system deficiencies.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBD462-2AE7-5279-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-74A1-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Mucolipidoses, not otherwise specified","valueDescription":"Not Otherwise Specified Mucolipidosis","ValueMeaning":{"publicId":"2685152","version":"1","preferredName":"Not Otherwise Specified Mucolipidosis","longName":"2685152v1.00","preferredDefinition":"Not characterized in any other way._A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Not Otherwise Specified","conceptCode":"C19594","definition":"Not characterized in any other way.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Mucolipidosis","conceptCode":"C61267","definition":"A group of inherited lysosomal storage diseases characterized by accumulation of lipids and carbohydrates in the tissues, resulting in mental disabilities and skeletal malformations.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-74B0-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-74C9-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Morquio (IV)","valueDescription":"Morquio Syndrome","ValueMeaning":{"publicId":"2593471","version":"1","preferredName":"Morquio Syndrome","longName":"2593471","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Morquio Syndrome","conceptCode":"C61263","definition":"A rare autosomal recessive lysosomal storage disease characterized by abnormal skeletal developments, dwarfism, heart disorders, and central nervous system deficits.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBEE5A-A52B-56E1-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-74D5-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Metachromatic leukodystrophy (MLD)","valueDescription":"Metachromatic Leukodystrophy","ValueMeaning":{"publicId":"2593450","version":"1","preferredName":"Metachromatic Leukodystrophy","longName":"2593450","preferredDefinition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Metachromatic Leukodystrophy","conceptCode":"C61251","definition":"An autosomal recessive inherited disorder characterized by abnormalities in the development of the myelin sheaths. It is caused by a deficiency of the enzyme arylsulfatase A. There are three forms of this disease: late infantile, juvenile, and adult. In the late infantile form symptoms include muscle weakness and rigidity, gait disturbances, developmental delays, and seizures. In the juvenile form symptoms include gait disturbances, mental deterioration and seizures. The adult form is characterized by psychotic symptoms and dementia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBABB0-0B0C-4B1B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-74EA-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Maroteaux-Lamy (VI)","valueDescription":"Maroteaux-Lamy Syndrome","ValueMeaning":{"publicId":"2593473","version":"1","preferredName":"Maroteaux-Lamy Syndrome","longName":"2593473v1.00","preferredDefinition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Maroteaux-Lamy Syndrome","conceptCode":"C61264","definition":"A rare autosomal recessive lysosomal storage disease caused by deficiency of the enzyme N-acetylgalactosamine-4-sulfatase. It is characterized by organomegaly, short stature, joint stiffness, otitis media, and respiratory illnesses.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD1FC2-696C-5FD0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-74F6-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Mannosidosis","valueDescription":"mannosidosis","ValueMeaning":{"publicId":"2579877","version":"1","preferredName":"mannosidosis","longName":"2579877v1.00","preferredDefinition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase. Clinical signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Mannosidosis","conceptCode":"C61275","definition":"A rare autosomal recessive lysosomal storage disease characterized by a deficient activity of the enzymes alpha-D-mannosidase or beta-mannosidase. Clinical signs and symptoms include hepatomegaly, splenomegaly, hearing loss, mental retardation, skeletal abnormalities, and recurrent respiratory infections.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0512-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7502-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Lesch-Nyhan (HGPRT deficiency)","valueDescription":"Lesch-Nyhan Syndrome","ValueMeaning":{"publicId":"2593456","version":"1","preferredName":"Lesch-Nyhan Syndrome","longName":"2593456v1.00","preferredDefinition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Lesch-Nyhan Syndrome","conceptCode":"C61255","definition":"An X-linked inherited syndrome caused by mutations in the gene that encodes the enzyme hypoxanthine-guanine phosphoribosyltransferase, resulting in accumulation of uric acid in the body. It affects males and is characterized by neurologic defects, moderate mental retardation, muscle hypotonia, and a tendency for self-mutilation (self-biting of lips, tongue, and fingertips).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBACE0-552C-4B7B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7517-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Krabbe disease (Globoid leukodystrophy)","valueDescription":"Krabbe Disease","ValueMeaning":{"publicId":"2593454","version":"1","preferredName":"Krabbe Disease","longName":"2593454","preferredDefinition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Krabbe Disease","conceptCode":"C61254","definition":"A rare inherited neurodegenerative disorder that belongs to the group of leukodystrophies. It is characterized by myelin destruction, gliosis in the brain, and the presence of multinucleated globoid cells. Signs and symptoms include irritability, mental and motor developmental disturbances, muscle weakness, seizures, blindness, and deafness.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC79-C5A9-4B39-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-752C-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"I-Cell Disease","valueDescription":"I-cell disease","ValueMeaning":{"publicId":"2579870","version":"1","preferredName":"I-cell disease","longName":"2579870v1.00","preferredDefinition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"I-Cell Disease","conceptCode":"C61270","definition":"An inherited lysosomal storage disease characterized by the presence of dense intracytoplasmic inclusions in mesenchymal cells, especially fibroblasts. Signs and symptoms include developmental delay, psychomotor deterioration, and growth failure.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-050B-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7538-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Hurler syndrome (IH)","valueDescription":"Hurler Syndrome","ValueMeaning":{"publicId":"2593465","version":"1","preferredName":"Hurler Syndrome","longName":"2593465v1.00","preferredDefinition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hurler Syndrome","conceptCode":"C61261","definition":"An autosomal recessive inherited disorder of mucopolysaccharide metabolism. It is the most severe form of mucopolysaccharidosis type I. It is characterized by deficiency of the enzyme alpha-L-iduronidase resulting in the accumulation of mucopolysaccharides in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBD4C4-3DC3-5287-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-754D-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Hunter syndrome (II)","valueDescription":"Hunter syndrome","ValueMeaning":{"publicId":"2582070","version":"1","preferredName":"Hunter syndrome","longName":"2582070v1.00","preferredDefinition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Hunter Syndrome","conceptCode":"C61260","definition":"An X-linked, inherited lysosomal storage disease caused by the deficiency of the enzyme iduronate sulfatase that is responsible for the degradation of mucopolysaccharides.  It nearly always affects males and is characterized by the accumulation of mucopolysaccharides in various organs, resulting in mental dysfunction, enlarged abdomen, hearing loss, obstructive airway disease, heart disease, and hepatosplenomegaly.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0DA3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-11-21","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-11-21","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7562-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Glucose storage disease","valueDescription":"glucose storage disease","ValueMeaning":{"publicId":"2579872","version":"1","preferredName":"glucose storage disease","longName":"2579872v1.00","preferredDefinition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Glycogen Storage Disease","conceptCode":"C61272","definition":"An inherited metabolic disorder characterized either by defects in glycogen synthesis or defects in the breaking down of glycogen. It results either in the creation of abnormal forms of glycogen or accumulation of glycogen in the tissues.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-050D-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-14","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7577-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Gaucher Disease","valueDescription":"Gaucher disease","ValueMeaning":{"publicId":"2579868","version":"1","preferredName":"Gaucher disease","longName":"2579868v1.00","preferredDefinition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Gaucher Disease","conceptCode":"C61268","definition":"An inherited lysosomal storage disease caused by deficiency of the enzyme glucocerebrosidase. It results in the accumulation of a fatty substance called glucocerebroside in mononuclear cells in the bone marrow, liver, spleen, brain, and kidneys. Signs and symptoms include hepatomegaly, splenomegaly, neurologic disorders, lymphadenopathy, skeletal disorders, anemia and thrombocytopenia.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0509-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-7583-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Fucosidosis","valueDescription":"fucosidosis","ValueMeaning":{"publicId":"2579876","version":"1","preferredName":"fucosidosis","longName":"2579876v1.00","preferredDefinition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Fucosidosis","conceptCode":"C61274","definition":"An autosomal recessive lysosomal storage disease characterized by a defective alpha-L-fucosidase. It results in accumulation of fucose in the tissues. Signs and symptoms include psychomotor retardation, dysostosis multiplex, and neural disturbances.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE88-0511-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-06-16","endDate":null,"createdBy":"IVERSONJ","dateCreated":"2006-06-16","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-758F-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Beta glucuronidase deficiency (VII)","valueDescription":"Beta glucuronidase deficiency (VII)","ValueMeaning":{"publicId":"2685153","version":"1","preferredName":"Beta glucuronidase deficiency (VII)","longName":"2685153","preferredDefinition":"A deficiency in the enzyme that splits glycosidic linkages in glucuronides.","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B969676-759B-1128-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-75B4-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Aspartyl Glucosaminuria","valueDescription":"Aspartylglycosaminuria","ValueMeaning":{"publicId":"2593486","version":"1","preferredName":"Aspartylglycosaminuria","longName":"2593486v1.00","preferredDefinition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Aspartylglycosaminuria","conceptCode":"C61273","definition":"A rare autosomal recessive lysosomal disorder characterized by deficiency of N-aspartyl-beta-glucosaminidase. It is characterized by developmental delays during childhood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BD5741-606F-6972-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"KUMMEROA","dateModified":"2023-08-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-75C9-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"},{"value":"Adrenoleukodystrophy (ALD)","valueDescription":"Adrenoleukodystrophy","ValueMeaning":{"publicId":"2593452","version":"1","preferredName":"Adrenoleukodystrophy","longName":"2593452","preferredDefinition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Adrenoleukodystrophy","conceptCode":"C61252","definition":"A rare metabolic disorder characterized by damage of the myelin sheaths in the nervous system and degeneration of the adrenal glands. It leads to progressive neurologic disorders, adrenal insufficiency and death.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"28BBAC12-A50B-4B21-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-02-05","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2007-02-05","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"3B969676-75D5-1128-E044-0003BA3F9857","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ALEYR","dateModified":"2007-10-03","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2685146","version":"1","preferredName":"Congenital Metabolic Disorder Osteopetrosis Type","preferredDefinition":"Errors in metabolic processes resulting from inborn genetic mutations that are inherited or acquired in utero.:Excessive formation of dense trabecular bone leading to pathological fractures, OSTEITIS, SPLENOMEGALY with infarct, ANEMIA, and extramedullary hemopoiesis (HEMATOPOIESIS, EXTRAMEDULLARY).:Type; a subdivision of a particular kind of thing.","longName":"C34816:C26840:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Congenital Metabolic Disorder","conceptCode":"C34816","definition":"A group of disorders present at birth that involve genetic defects leading to disturbances in carbohydrate, lipid, lysosomal storage or amino acid metabolism in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Osteopetrosis","conceptCode":"C26840","definition":"A rare genetic disorder inherited in an autosomal dominant, autosomal recessive, or X-linked recessive pattern. In the majority of cases it is caused by mutations in the CLCN7, TCIRG1, or IKBKG genes. It is characterized by excessive bone formation due to the failure of osteoclasts to resorb bone. It manifests with deformities, fractures, hepatosplenomegaly, anemia, and extramedullary hematopoiesis.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B9695F0-3A2F-052B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"ONEDATA","dateModified":"2007-10-03","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B9695F0-3A40-052B-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"CURTIST","dateModified":"2011-04-13","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"pre_ted_who_metab_osteopt","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedDiagnosis:value","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"What was the classification o","type":"Preferred Question Text","description":"What was the classification of the inherited disorders of metabolism / osteopetrosis?","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:2685168","type":"BRIDG Mapping Path","description":"PerformedDiagnosis.value(ANY=>CD).code","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"3B96C0A4-2500-191A-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2007-10-03","endDate":null,"createdBy":"ALEYR","dateCreated":"2007-10-03","modifiedBy":"KUMMEROA","dateModified":"2021-05-03","changeDescription":". 2021-5-3 ak System generated def displayed as alt def.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}